The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. Charles Schwab is an online brokerage firm that offers a wide range of services for new ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...